Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels.
about
The antibody targeting the E314 peptide of human Kv1.3 pore region serves as a novel, potent and specific channel blockerKCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targetingPotassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion.Ion channel trafficking: a new therapeutic horizon for atrial fibrillationIdentification of selective inhibitors of the potassium channel Kv1.1-1.2((3)) by high-throughput virtual screening and automated patch clamp.Inhibition of cardiac Kv1.5 potassium current by the anesthetic midazolam: mode of action.Potent suppression of Kv1.3 potassium channel and IL-2 secretion by diphenyl phosphine oxide-1 in human T cells.RNA polymerase III drives alternative splicing of the potassium channel-interacting protein contributing to brain complexity and neurodegenerationImproved functional expression of human cardiac kv1.5 channels and trafficking-defective mutants by low temperature treatmentSide pockets provide the basis for a new mechanism of Kv channel-specific inhibition.Specific Kv1.3 blockade modulates key cholesterol-metabolism-associated molecules in human macrophages exposed to ox-LDL.Structural determinants of Kvbeta1.3-induced channel inactivation: a hairpin modulated by PIP2.Interaction of local anesthetics with the K (+) channel pore domain: KcsA as a model for drug-dependent tetramer stabilityInhibitory actions of the phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channel.Structural basis of ion permeation gating in Slo2.1 K+ channels.Sodium permeable and "hypersensitive" TREK-1 channels cause ventricular tachycardia.Polyunsaturated Fatty acids modify the gating of kv channelsThe voltage-dependent K(+) channels Kv1.3 and Kv1.5 in human cancer.Silencing of Kv1.5 Gene Inhibits Proliferation and Induces Apoptosis of Osteosarcoma Cells.Molecular Basis of Cardiac Delayed Rectifier Potassium Channel Function and Pharmacology.Cardiac Delayed Rectifier Potassium Channels in Health and Disease.Dynamics and modulation studies of human voltage gated Kv1.5 channel.Putative binding sites for arachidonic acid on the human cardiac Kv 1.5 channel.Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1.Antiarrhythmic drug-induced internalization of the atrial-specific k+ channel kv1.5.Kv1.5 in the immune system: the good, the bad, or the ugly?Characterizing the fatty acid binding site in the cavity of potassium channel KcsAOverlapping binding sites of structurally different antiarrhythmics flecainide and propafenone in the subunit interface of potassium channel Kv2.1.Mechanism of block of hEag1 K+ channels by imipramine and astemizole.RNA editing modulates the binding of drugs and highly unsaturated fatty acids to the open pore of Kv potassium channels.Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state--docking and computer simulations of a homology model.Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?Regulation of human cardiac Kv1.5 channels by extracellular acidification.Pharmacophore Mapping for Kv1.5 Potassium Channel BlockersStrategies for atrial fibrillation therapy: focusing onIKurpotassium channel
P2860
Q28482737-EF9E941C-26A6-4BE6-919A-E474C88F4EA9Q28822031-59CEE578-9397-415D-9D05-E380476E966DQ30497371-FDABC37E-7E43-4D54-AD20-9ECA57694324Q34101658-CE814D75-8A44-49B7-8A10-2E2129161A57Q34219538-2BEF4619-BB3A-4F48-877B-3C723320F285Q34511484-B18B0FAA-C628-4F77-A9ED-EAFEAD1596C9Q34746164-7C3363F5-0360-473A-A2F0-219DE5D83F86Q35018234-2F585CA8-4639-4009-B8C2-542B33C78EE7Q35129668-8E9D83C4-9B0B-438F-9936-3E6CD0F433FAQ35963307-62EB983E-9DF7-48F6-81E3-12CA32EBF5C6Q36462111-A37FA54E-FF20-46BD-9608-40C883E5B5FBQ37008347-128783DB-1DC3-4126-94C4-85B2C6A973E7Q37009060-0C251CAB-0C90-4E25-818D-9AA9ACC4F013Q37230979-AF62B429-BEF1-47BA-A153-A12FFBC73574Q37268772-6F78FBAB-AC38-4510-B873-DC002F016BDDQ37733999-D223D9FC-065B-40A5-A84E-6F39AAAB9C6DQ38042919-85AC5C66-7516-4C35-9496-BCDCAB1F815DQ38153378-E309D7FF-C591-46EF-8D9B-1D9DE5EE6063Q38819509-DD8FA137-8796-4EE6-A321-0D629C161D5AQ38854244-AAA0969F-31B9-4CC3-9D30-3B8884BFC2E0Q38854252-7EBE7056-FFCC-425A-879C-83BFFCA38913Q38918724-44C38A0A-B73E-4D5A-B2D1-184A31420A22Q38972404-D11D3D54-B542-4E5F-B62B-5951110C86A6Q39639701-818B29CA-4DA9-4DA7-BA16-EC859241CDB9Q39851183-8CA3BE6E-0DD6-4880-A262-C86BFC99D674Q41788733-C62D7C6F-7080-40FC-B3FC-2136D2D80CFFQ41822118-99E66B62-97A3-4DD9-951B-67B681A09988Q41833846-E5D1BB94-BC95-41E7-A93D-C37428155F71Q41952692-C4DD36B4-7152-4A34-8939-D66A3F77D545Q42165768-383C26A2-B33E-4320-A9AA-9AB1F418AE3EQ42633034-A3559163-37BA-4EA0-81A4-88F9799F6931Q48007771-B827BF47-BEFA-4A3C-B727-8D957FEAC753Q51354497-592E3B22-E686-484E-8F88-91D0E7F9F7F5Q58860323-49952119-E1DC-49B5-80D0-2588790BA016Q58860331-633C8B74-4EE8-44B7-A467-2573805F40EC
P2860
Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Molecular basis for Kv1.5 chan ...... ong voltage-gated K+ channels.
@en
Molecular basis for Kv1.5 chan ...... ong voltage-gated K+ channels.
@nl
type
label
Molecular basis for Kv1.5 chan ...... ong voltage-gated K+ channels.
@en
Molecular basis for Kv1.5 chan ...... ong voltage-gated K+ channels.
@nl
prefLabel
Molecular basis for Kv1.5 chan ...... ong voltage-gated K+ channels.
@en
Molecular basis for Kv1.5 chan ...... ong voltage-gated K+ channels.
@nl
P2093
P2860
P356
P1476
Molecular basis for Kv1.5 chan ...... ong voltage-gated K+ channels.
@en
P2093
Andreas E Busch
Bernard Pirard
Florian Bundis
Klaus Steinmeyer
Michael C Sanguinetti
Niels Decher
Stefan Peukert
P2860
P304
P356
10.1074/JBC.M307411200
P407
P577
2003-10-25T00:00:00Z